Researchers say the success identifying acute respiratory distress syndrome, or ARDS, shows the promise of AI diagnostics ...

Researchers developed and evaluated a deep learning model for predicting coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS).

Convalescent plasma reduced mortality in COVID-19 patients with acute respiratory distress syndrome (ARDS) when provided within 5 days of invasive mechanical ventilation, the randomized open-label ...

The ARDS group included SARS-CoV-2 patients who required mechanical ventilation during their ICU stay, whereas the non-ARDS group included COVID-19 patients with mild to moderate symptoms.

A total of 25,677 (12.1%) cases of long COVID occurred among reinfected participants and 18,460 (8.7%) long-COVID cases ...

Treatment with convalescent plasma reduced 28-day mortality among adults undergoing mechanical ventilation for COVID-19-induced acute respiratory distress syndrome, according to results published ...

Key takeaways: Survival rates following transplantation did not differ between those with COVID-19 related ARDS or pulmonary fibrosis. Both groups also had similar rates of freedom from graft failure.

Changes in pre-ECMO therapy between the first and second waves of COVID-19 or greater disease severity among patients on ECMO may explain the differences in outcomes, critical care specialists said.

More Mortality After ECMO COVID-19 changed the survival equation for ARDS patients put on ECMO in an analysis of the National Inpatient Sample (NIS) database.

“The potential for ExoFlo to treat patients with ARDS represents an advancement in efforts to reduce morbidity and mortality caused by the serious inflammatory complications of COVID-19.” ...